New In­di­ca­tions

Pharmacy Daily - - News -

Abi­raterone ac­etate (Zytiga) is now in­di­cated in com­bi­na­tion with pred­nisone or pred­nisolone for the treat­ment of newly di­ag­nosed high risk metastatic hor­mone sen­si­tive prostate can­cer in com­bi­na­tion with an­dro­gen de­pri­va­tion ther­apy.

Evolocumab (rch) (Repatha) is now in­di­cated in adults with non-fa­mil­ial hy­per­c­holes­tero­laemia to re­duce low den­sity lipopro­tein choles­terol; in adults with es­tab­lished car­dio­vas­cu­lar dis­ease (in com­bi­na­tion with an op­ti­mally dosed statin and/or other lipid low­er­ing ther­a­pies) to re­duce the risk of car­dio­vas­cu­lar events (my­ocar­dial in­farc­tion, stroke and coro­nary revas­cu­lar­i­sa­tion).

La­cosamide (Vim­pat, Vim­pat In­jec­tion) is now in­di­cated as monother­apy in the treat­ment of par­tial seizures with or with­out sec­ondary gen­er­al­i­sa­tion in pa­tients with epilepsy aged 16 years and older, and as add-on ther­apy in pa­tients with epilepsy aged 4 years and older. Lu­macaftor/iva­caftor (Orkambi) is now in­di­cated for the treat­ment of cys­tic fi­bro­sis in pa­tients aged 6 years and older who are ho­mozy­gous for the F508del mu­ta­tion in the CFTR gene.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.